Oklahoma Health Care Authority; Insulin Access and Affordability Program; effective date; emergency.

Changed eligibility criteria from allowing both nonprofit and for-profit manufacturers to only nonprofit pharmaceutical companies for insulin development agreements.

Modified program requirements to specify nonprofit organizations must provide biosimilar insulin at prices not exceeding $30 per vial and $55 per pack of five pre-filled insulin pens.

Added requirement for memoranda of understanding to identify estimated savings to Oklahoma residents and self-insureds from affordable insulin availability.

Added requirement for nonprofit organizations to state the amount or percentage of matching funds provided in relation to state appropriated funds.

Established effective date of July 1, 2025, and declared emergency status for immediate implementation upon passage and approval.

Expanded eligible participants from only nonprofit pharmaceutical companies to include both not-for-profit and for-profit manufacturers.

Removed the 'fast-acting' qualifier from insulin references, making the program applicable to all insulin types.

Updated requirements for memoranda of understanding to allow agreements with for-profit manufacturers in addition to nonprofit organizations.

Document title changed from 'PROPOSED COMMITTEE SUBSTITUTE' to 'COMMITTEE SUBSTITUTE'

Request number updated from 12879 to 12956

Date updated from 02/25/25 to 02/26/25

Page numbering and formatting were adjusted throughout the document

Emergency declaration title was updated to include bill subject matter

Document formatting and header information were updated to reflect committee amendment status, including changes to bill title, sponsor information, and page numbering.

The document type changed from 'Engrossed House' to 'Proposed Committee Substitute' with updated committee amendment markings and reading clerk information.

The core legislative text creating the Insulin Access and Affordability Program, including program purposes, authority to enter agreements with pharmaceutical companies and nonprofit organizations, and pricing thresholds, remains identical to the original version.

Bill title and purpose changed from general health appropriations to specifically address insulin access and affordability.

New requirements added for the State Department of Health to enter agreements with nonprofit pharmaceutical companies to accelerate fast-acting insulin development and maintain prices under $30 per vial and $55 per pack of five pens.

Added requirement for nonprofit partners to identify estimated savings to Oklahoma residents and state the percentage of matching funds provided.

Funding amount changed from $1,100,000 for general purposes to $340,222 specifically for federally qualified health centers under the new insulin program.

Effective date section renumbered from Section 3 to Section 2, maintaining July 1, 2025 as the effective date.